Akebia Therapeutics, a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, entered into a senior secured term loan facility with Symbiotic Capital. The loan facility consists of an initial tranche of $60 million that was fully funded at closing and the ability to request up to an additional $80 million, which Symbiotic Capital may fund at its discretion.
The Symbiotic loan facility closed on Nov. 12, 2026. Akebia used the proceeds from the initial tranche to repay in full its $55 million loan facility with BlackRock. The loan facility has a 60-month maturity, a 60-month interest-only period with principal due at maturity and bears interest at a variable monthly interest rate equal to the greater of WSJ Prime plus 4.5% or 11.5%.
“We are very pleased to announce this financing which enhances our operational flexibility and gives us the potential to access additional non-dilutive capital to advance our strategic initiatives. Today, we also reaffirm our cash runway guidance of at least two years,” Erik Ostrowski, Akebia’s chief financial and chief business officer, said. “We are excited to partner with Symbiotic Capital, whose deep expertise in healthcare financing makes them an ideal collaborator. We are also very appreciative of our partnership with BlackRock over the past several years.”
Chris York, senior managing director at Symbiotic Capital, added, “Akebia has a portfolio of revenue-generating products and a pipeline focused on kidney disease, led by a management team with deep experience in the space. We are pleased to provide this financing and look forward to supporting Akebia as it executes on its business strategy.”





